We currently have numerous trials enrolling new participants. They include:
- Acne (Facial)
- Acne (Facial, Back, Chest)
- Anal Cancer Prevention in HIV Patients
- Cognitive Impairment/Dementia
- Crohn’s Disease
- Diabetes Mellitus (Type 1)
- Iron Deficiency Anemia
- Migraine Headache
- Restless Legs Syndrome
- Rheumatoid Arthritis
If you decide to take part in a clinical trial and are enrolled, you will receive confidential study-related medical care and treatment at no cost. Visits will be at The Polyclinic and free parking is provided. Financial compensation for time and travel may also be available.
We appreciate your interest and welcome the opportunity to speak with you directly. Please contact us at:
- Phone: 206-320-6692
- Email: email@example.com
Dr. Kim Abson is conducting a study evaluating an investigational foam for the treatment of facial acne. Patients must be 9 years of age or older and have moderate-to-severe facial acne. Learn more.
Dr. Kim Abson is conducting a study evaluating an investigational cream for the treatment of facial and truncal (back and chest) acne. Patients between 9 and 11 years must have moderate facial acne and patients 12 years and older must have moderate facial and truncal acne. Learn more.
Dr. Juan de la Ossa is conducting a study comparing topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. It is not yet known if treating HSIL is more effective than active monitoring in preventing patients from developing anal cancer. Learn more.
Dr. Braden Nago is conducting a study assessing how the results of an amyloid PET scan may impact treatment decisions. To be eligible patients must have mild cognitive impairment (MCI) or dementia of uncertain cause and be a Medicare beneficiary, 65 years of age or older. Enrolled patients will have one amyloid PET scan followed by one visit with Dr. Nago to discuss the results of the scan and future treatment. Medicare has agreed to cover the cost of the scan for this study. The scan is FDA approved and not considered investigational. Learn more.
Dr. Peggy Headstrom is conducting a study evaluating an investigational drug in causing clinical remission of Crohn’s disease. Patients must have moderate to severe Crohn’s disease and have failed or be intolerant to anti-tumor necrosis factor-alpha therapy. Learn more.
Dr. Ken Gross is conducting a study evaluating an investigational drug in controlling blood glucose in patients with Type 1 diabetes already using insulin therapy. Patients must have been receiving insulin for the treatment of Type 1 diabetes for at least one year. Learn more.
Dr. Lisa Nakamoto is conducting a study comparing Feraheme® (ferumoxytol injection) to Injectafer® (ferric carboxymaltose injection) for the treatment of iron deficiency anemia (IDA). Patients must have IDA and an intolerance to oral iron or have had unsatisfactory response to oral iron. Both Feraheme and Injectafer are an iron replacement product indicated for the treatment of IDA. Learn more.
Dr. Braden Nago is conducting a study evaluating an investigational drug in the acute treatment of migraine headache. Patients must have a history of migraine headaches of at least one year, and migraine onset before age 50. Learn more.
Dr. Meghana Doreswamy is conducting a study evaluating Injectafer® (ferric carboxymaltose injection) for the treatment of restless legs syndrome (RLS). Patients must have RLS symptoms affirming diagnosis. Injectafer is an iron replacement product indicated for the treatment of iron deficiency anemia. Its use for the treatment of RLS is investigational. Learn More.
Dr. Anthony Krajcer is conducting a study to determine whether using results from a blood test called Vectra DA to guide drug dosing strategies can lower healthcare costs, without a negative impact on health and well-being, when compared to usual care. Patients must have active rheumatoid arthritis, and have not responded fully to methotrexate (MTX). Learn more.